Zacks44d agobearish
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock FallsOCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
89last 24h
958last 7d
108● bullish (7d)
117● bearish (7d)
212publishers
Zacks138d agobearish
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookOcugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.